Tomoko Warita

Sanda, 6691330, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Effects of Low-Dose Atorvastatin on Hypoxic Response in Statin-Sensitive and Statin-Resistant Cancer Cells.

Effects of Low-Dose Atorvastatin on Hypoxic Response in Statin-Sensitive and Statin-Resistant Cancer Cells.

Journal: Biological & pharmaceutical bulletin

Published: August 20, 2025

Exploration of Novel Metabolic Features Reflecting Statin Sensitivity in Lung Cancer Cells.

Exploration of Novel Metabolic Features Reflecting Statin Sensitivity in Lung Cancer Cells.

Journal: Biological & pharmaceutical bulletin

Published: December 08, 2024

Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines.

Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines.

Journal: Biomedicines

Published: February 24, 2024

Comparison of the anticancer effects of various statins on canine oral melanoma cells.

Comparison of the anticancer effects of various statins on canine oral melanoma cells.

Journal: Veterinary and comparative oncology

Published: August 19, 2023

Housekeeping gene expression variability in differentiating and non-differentiating 3T3-L1 cells.

Housekeeping gene expression variability in differentiating and non-differentiating 3T3-L1 cells.

Journal: Adipocyte

Published: July 12, 2023

HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.

HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.

Journal: Biochemical and biophysical research communications

Published: June 06, 2023

CYP11A1 silencing suppresses HMGCR expression via cholesterol accumulation and sensitizes CRPC cell line DU-145 to atorvastatin.

CYP11A1 silencing suppresses HMGCR expression via cholesterol accumulation and sensitizes CRPC cell line DU-145 to atorvastatin.

Journal: Journal of pharmacological sciences

Published: April 10, 2023

The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F.

The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F.

Journal: Biochemical and biophysical research communications

Published: April 07, 2023

Expression of housekeeping genes varies depending on mevalonate pathway inhibition in cancer cells.

Expression of housekeeping genes varies depending on mevalonate pathway inhibition in cancer cells.

Journal: Heliyon

Published: January 19, 2023

Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.

Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.

Journal: Genes

Published: December 27, 2022

Alterations in the omics profiles in mevalonate pathway-inhibited cancer cells.

Alterations in the omics profiles in mevalonate pathway-inhibited cancer cells.

Journal: Life sciences

Published: October 18, 2022

Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells.

Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells.

Journal: Veterinary and comparative oncology

Published: August 04, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026